Duration of IOP Reduction With Travoprost BAK-free Solution

Gross, Ronald L.; Peace, James; Smith, Stephen; Walters, Thomas R.; DuBiner, Harvey; Weiss, Marc A.; Ochsner, Katherine I.

doi:10.1097/ijg.0b013e31815a3472

Cited by 57 publications

(40 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…that the two formulations of travoprost (travoprost with BAK and travoprost BAK-free) had similar effi cacy, including a prolonged duration of action showing Ͼ6 mmHg reduction in IOP 60 hours after fi nal dose of either drug (Gross et al 2008). However, physicians must interpret the effi cacy data from the current trial with caution because of its open-label design, which may have introduced bias into the results for IOP.…”

Section: Discussionmentioning

confidence: 85%

Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy

Henry

Peace²,

Stewart³

et al. 2008

OPTH

View full text Add to dashboard Cite

Purpose: To evaluate the effi cacy, safety and tolerability of changing to travoprost BAK-free from prior prostaglandin therapy in patients with primary open-angle glaucoma or ocular hypertension. Design: Prospective, multi-center, historical control study. Methods: Patients treated with latanoprost or bimatoprost who needed alternative therapy due to tolerability issues were enrolled. Patients were surveyed using the Ocular Surface Disease Index (OSDI) to evaluate OSD symptoms prior to changing to travoprost BAK-free dosed once every evening. Patients were re-evaluated 3 months later. Results: In 691 patients, travoprost BAK-free demonstrated improved mean OSDI scores compared to either latanoprost or bimatoprost (p Ͻ 0.0001). Patients having any baseline OSD symptoms (n = 235) demonstrated signifi cant improvement after switching to travoprost BAK-free (p Ͻ 0.0001). In 70.2% of these patients, symptoms were reduced in severity by at least 1 level. After changing medications to travoprost BAK-free, mean intraocular pressure (IOP) was signifi cantly decreased (p Ͻ 0.0001). Overall, 72.4% preferred travoprost BAK-free (p < 0.0001, travoprost BAK-free vs prior therapy). Travoprost BAK-free demonstrated less conjunctival hyperemia than either prior therapy (p Ͻ 0.0001). Conclusions: Patients previously treated with a BAK-preserved prostaglandin analog who are changed to travoprost BAK-free have clinically and statistically signifi cant improvement in their OSD symptoms, decreased hyperemia, and equal or better IOP control.

show abstract

Section: Discussionmentioning

confidence: 85%

Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy

Henry

Peace²,

Stewart³

et al. 2008

OPTH

View full text Add to dashboard Cite

show abstract

“…[41][42][43] In particular, Hamacher et al 41 in a pharmacodynamics analysis did not find statistically significant differences between BAK-free and BAKcontaining formulations in the incidence of ocular adverse events comparing preservative-free tafluprost with tafluprost containing 0.01% BAK. Also, in the work of Gross et al 42 , travoprost BAK free and travoprost preserved with BAK showed no differences in the safety and Lewis et al 43 have demonstrated no differences in the incidence of side ocular effects, comparing travoprost 0.004% containing 0.015% BAK with travoprost 0.004% BAK free.…”

Section: Discussionmentioning

confidence: 99%

Bimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patients

Figus

Nardi

Piaggi

et al. 2014

Eye

View full text Add to dashboard Cite

Results Global clinical score (the sum of pruritus, stinging/burning, blurred vision, sticky eye sensation, eye dryness sensation, and foreign body sensation) significantly decreased in the bimatoprost 0.01% group from baseline 4.7±3.8 to 2.9±2.3 (Po0.001) and 2.5±2.0 (Po0.001) at 6-month and 12-month follow-ups, respectively. Comparison between groups showed differences at both follow-up visits (P ¼ 0.003 and Po0.001, respectively). In vivo confocal microscopy revealed a significant increase in goblet cell density in the bimatoprost 0.01% group compared with the bimatoprost 0.03% group (Po0.001 at both follow-up visits). All functional parameters and conjunctival hyperemia improved in the bimatoprost 0.01% group at each follow-up visit (Po0.05) and in comparison with bimatoprost 0.03% (Po0.05). ConclusionThe results of this trial suggest that bimatoprost 0.01% eye drops seem to decrease the ocular discomfort with respect to bimatoprost 0.03% eye drops.

show abstract

“…196,197 This results in a longer duration, clinically useful, IOP-lowering effect of both original travoprost and the BAK-free version. 180,198,199 This could be important in patients who occasionally miss doses. The functional activities of the HLs are shown in Fig.…”

Section: Hypotensive Lipidsmentioning

confidence: 98%

Medications Used to Treat Glaucoma

Schacknow

Samples

2010

The Glaucoma Book

View full text Add to dashboard Cite

ConclusionOptimal therapy for glaucoma would involve IOP control throughout the 24-h period. However, not all therapies are equally efficacious at all times of the day and night. Understanding of the mechanisms of action of different therapies, along with the knowledge of the circadian changes in aqueous humor dynamics, allows us to predict the therapies that will provide the most consistent IOP reduction. As well, understanding of aqueous humor dynamics may help in the development of future therapies with consistent 24-h IOP control. Bibliography

show abstract

Duration of IOP Reduction With Travoprost BAK-free Solution

Cited by 57 publications

References 21 publications

Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy

Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy

Bimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patients

Medications Used to Treat Glaucoma

Contact Info

Product

Resources

About